AUS
NZ
UK
CA
USA
IND
Highlights
- Mayne Pharma (ASX:MYX) receives a $7.40 per share acquisition offer from Cosette Pharma.
- The deal represents a 37% premium to Mayne Pharma’s last closing price.
- The acquisition expands Cosette Pharma’s portfolio and global presence in women’s health and dermatology.
Mayne Pharma (ASX:MYX) has received a $672 million takeover offer from US-based pharmaceutical company Cosette Pharma, valuing its shares at $7.40 each. This deal highlights Mayne Pharma’s progress in enhancing patient access to essential medications while also marking a significant step for Cosette Pharma in expanding its global footprint.
Strategic Growth and Expansion
Cosette Pharma, known for its strong presence in dermatology and women’s health, has a long history of manufacturing complex dosage forms, including topical creams, ointments, oral solutions, and suppositories. The company is backed by healthcare-focused private equity firm Avista Healthcare Partners and investment management firm Hamilton Lane.
With corporate and manufacturing facilities in New Jersey and North Carolina, Cosette Pharma has a workforce of over 350 professionals. The acquisition aligns with its strategic goal of strengthening its expertise in key therapeutic areas while enhancing its global reach.
Board’s Endorsement and Shareholder Benefits
Mayne Pharma’s board has unanimously recommended shareholders vote in favor of the acquisition. Chair Frank Condella acknowledged the strong efforts taken by the company to build value over the past year and emphasized that the offer reflects this success.
The $7.40 per share proposal represents a 37% premium to Mayne Pharma’s closing stock price as of February 20, 2025, and a 42% premium to the 30-day volume-weighted average price. The board believes the deal provides strong financial returns while securing long-term benefits for stakeholders.
Strengthening Market Position
For Cosette Pharma, this acquisition represents a key move to reinforce its leadership in women’s health within the US while accelerating global expansion. CEO Apurva Saraf highlighted that integrating Mayne Pharma’s commercial expertise with Cosette’s portfolio will create a company poised for innovation and sustained growth.
The combined entity aims to invest further in product development and portfolio expansion while improving patient access to critical medications. With shareholder approval still pending, this deal could mark a transformative phase for both companies, fostering innovation and broader market opportunities.
